Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. develops investigational therapies for endocrine conditions and neurodegenerative diseases with high unmet medical need. News about AMLX centers on its clinical-stage pipeline, including avexitide, a GLP-1 receptor antagonist being evaluated for post-bariatric hypoglycemia, and additional programs such as AMX0035, AMX0114 and AMX0318.
Recurring company updates cover clinical trial progress, expanded access activity, development-candidate selections, program discontinuations, quarterly financial results and investor presentations. Amylyx news also reflects regulatory and commercial-readiness topics tied to investigational therapies, collaboration updates and capital-runway commentary typical of a biotechnology issuer advancing multiple development programs.
Amylyx Pharmaceuticals (AMLX) has announced that its Marketing Authorisation Application for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS), has been validated by the European Medicines Agency (EMA) and is now under review. The application is supported by positive data from the CENTAUR trial, which indicated that AMX0035 reduced clinical decline and improved survival rates compared to placebo. The company is preparing its European team for a potential launch pending a favorable review outcome.
Amylyx Pharmaceuticals has appointed Gina M. Mazzariello as its new Chief Legal Officer and General Counsel. Ms. Mazzariello brings over 20 years of experience in healthcare law, including extensive knowledge in drug commercialization and regulatory matters. Prior to joining Amylyx, she served at Boehringer Ingelheim USA, where she led legal operations for the human pharmaceuticals division. Her expertise is expected to facilitate Amylyx's global expansion and regulatory approvals, reinforcing their commitment to the neurodegenerative community.
Amylyx Pharmaceuticals announced a virtual FDA advisory committee meeting on March 30, 2022, to review the New Drug Application (NDA) for AMX0035, an investigational therapy for amyotrophic lateral sclerosis (ALS). The FDA has prioritized this review with a Prescription Drug User Fee Act date set for June 29, 2022. AMX0035 is a combination of sodium phenylbutyrate and taurursodiol, aimed at reducing neuronal death in ALS. The company anticipates a thorough scientific discussion on the clinical data backing their application.
Amylyx Pharmaceuticals will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 4:20 PM ET. Co-CEOs Joshua Cohen and Justin Klee will host the virtual presentation. Interested parties can access a live webcast through the Company’s investor section on their website, with a replay available for 90 days post-event.
Amylyx is focused on developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Amylyx Pharmaceuticals (NASDAQ: AMLX) has partnered with the Canadian Neuromuscular Disease Registry (CNDR) for a real-world evidence initiative concerning its investigational therapy, AMX0035, aimed at treating amyotrophic lateral sclerosis (ALS). This collaboration will collect demographic, clinical, functional, and survival data on ALS patients using AMX0035 across Canada. The partnership is expected to generate valuable insights into AMX0035's impact on ALS treatment, enhancing patient access to therapies and potentially shaping future treatment protocols.